19 January 2016: promotion of Voltarol by GSK/Novartis Consumer Health UK
Published 22 March 2016
© Crown copyright 2016
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-february-2016/19-january-2016-promotion-of-voltarol-by-gsknovartis-consumer-health-uk
Olswang LLP complained about claims made on the Voltarol website, packaging and television advert produced by Novartis Consumer Health/GSK. The complainant alleged that claims were not in line with the summary of product characteristics, were not substantiated or that they promoted a prescription only medicine to the public.
MHRA did not uphold the complaint. We considered that the material presented the SPC information in patient friendly language but advised Novartis/GSK to remove one mention of tablets.